Fed. Circ. Backs Generic Co.'s IP Win Over Eagle Cancer Drug
The Federal Circuit ruled in a precedential opinion Friday that a generic version of the cancer drug Belrapzo did not infringe patents owned by Eagle Pharmaceuticals, faulting Eagle for disclosing the...To view the full article, register now.
Already a subscriber? Click here to view full article